They are made based on a personalized prescription that may not be commercially available elsewhere or when a drug appears on the FDAs shortage list
8th edition, January 2017, 50.WHO
121 The National Cholesterol Education Program 122 and American Heart Association 123 both support the use of sterols in their dietary recommendations
Some users achieve their weight loss goals at lower doses and never need the maximum
Dikshita D, Renata DI, Giacomo Carlo S, Alakesh D, Surajit P, Antara B
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
